Two cytokines from fluid in the anterior chamber of the eye help predict response to the anti–vascular endothelial growth factor drug ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME), new research suggests, according to a report in Medscape.
If validated, the biomarkers could spare patients repeated injections with an ineffective agent, but one expert expressed concern about the invasiveness of the test.
"The prospect of ongoing injections in the eye is daunting for patients," senior author Rajeev Muni, MD, a vitreoretinal surgeon at St. Michael's Hospital, Toronto, Ontario, Canada, said in a statement. "The fact that we can now measure a protein in the eye that allows us to predict which patients are less likely to respond to treatment could lead to more personalized and tailored medicine and fewer injections. This could alleviate the treatment burden on patients and the healthcare system," he added.